Strides Pharma Science (NSE:STAR) Total Receivables: ₹12,971 Mil (As of Mar. 2026)


NSE:STAR Strides Pharma Science Ltd NSE:STAR
67 GF Score
Price ₹1,092.90
GF Value ₹775.20
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Strides Pharma Science Total Receivables?

Strides Pharma Science NSE:STAR -0.95% 67 Total Receivables is ₹12,971 Mil as of Mar. 2026. GuruFocus rates NSE:STAR with a GF Score™ of 67/100 and a GF Value™ of ₹775.20 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Strides Pharma Science's Total Receivables for the quarter that ended in Mar. 2026 was ₹12,971 Mil.

Strides Pharma Science Total Receivables Related Terms

Strides Pharma Science Total Receivables Historical Data

* Premium members only.

The historical data trend for Strides Pharma Science's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strides Pharma Science Total Receivables Chart

Strides Pharma Science Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18,049.28 14,088.16 13,031.51 14,194.58 12,971.00

Strides Pharma Science Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14,194.58 0.00 11,437.86 0.00 12,971.00
NSE:STAR
67GF Score
Strides Pharma Science Ltd NSE:STAR
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strides Pharma Science Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹12,971 Mil mean?
Strides Pharma Science (NSE:STAR) has a Total Receivables of ₹12,971 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Strides Pharma Science and its competitors.
Is Strides Pharma Science's Total Receivables too high?
Strides Pharma Science's current Total Receivables is ₹12,971 Mil. Overall, Strides Pharma Science has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's Total Receivables compare to ZTS and UTHR?
Strides Pharma Science's Total Receivables of ₹12,971 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Strides Pharma Science and its competitors. Strides Pharma Science's current Total Receivables is ₹12,971 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹775.20, compared to a current price of ₹1,092.90 — trading 41% above its estimated fair value. The current Total Receivables is ₹12,971 Mil. Strides Pharma Science's overall GF Score™ is 67/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current Total Receivables is ₹12,971 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?

Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued. The current stock price of ₹1,092.90 is trading 41% above its estimated GF Value™ of ₹775.20. GuruFocus considers Strides Pharma Science to be Significantly Overvalued.

Key valuation signals for NSE:STAR:

  • Total Receivables: ₹12,971 Mil
  • GF Value™: ₹775.20 vs. price of ₹1,092.90 (41% above fair value)
  • GF Score™: 67/100 with 4 warning signs

No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Strides Pharma Science Business Description

Other Exchanges 532531:India
Address Bannerghatta Road, Strides House, Bilekahalli, Bengaluru, KA, IND, 560076
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
67GF Score

Get the complete analysis for NSE:STAR

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,092.90
Price
₹775.20
GF Value